The effect of chromium on inflammatory markers, 1st and 2nd phase insulin secretion in type 2 diabetes

Chen, Yen‐Lin; Lin, Jiunn Diann; Hsia, Te Lin; Mao, Frank Chiahung; Hsu, Chiun; Pei, Dee

doi:10.1007/s00394-013-0508-8

Cited by 31 publications

(20 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Next, 172 titles and the abstracts were screened; of these, 47 publications were considered relevant and the full‐text articles were obtained. After careful assessment, a total of 28 RCTs that met our inclusion criteria were included in the present pooled analysis . Reasons for rejecting the other eight articles were listed in Supporting Information Fig.…”

Section: Resultsmentioning

confidence: 99%

Chromium supplementation for adjuvant treatment of type 2 diabetes mellitus: Results from a pooled analysis

Huang

Chen²,

Dong

et al. 2017

Molecular Nutrition Food Res

View full text Add to dashboard Cite

Scope:We conducted a pooled analysis of randomized controlled trials to evaluate the effects of chromium supplementation on clinically relevant metabolic biomarkers in type 2 diabetes mellitus (T2DM) patients. Methods and results: Electronic searches were conducted and the bibliographies of located articles were searched, and 28 studies were suitable for statistical pooling. Endpoints were calculated as weighted mean differences (WMDs) with 95% confidence intervals (CIs) by using fixed-effects or random-effects models. Statistical heterogeneity, publication bias, subgroup analyses, sensitivity analysis and meta-regression assessments were also assessed. Chromium reduced levels of fasting plasma glucose (WMD, −0.99 mmol/L; 95% CI, −1.72 to −0.25; p = 0.008), hemoglobin A1c (WMD, −0.54 %; 95% CI, −0.82 to −0.25; p = 0.0002), triglycerides (WMD, −11.71 mg/dL; 95% CI, −18.38 to −5.04; p = 0.0006). Chromium also increased levels of high-density lipoprotein cholesterol (WMD, 1.73 mg/dL; 95% CI, 0.50 to 2.96; p = 0.006). These results were robust in sensitivity analysis and were not dependent on the chromium dose and duration of supplementation. Subgroup analyses indicated that these notably favorable effects were presented in T2DM subjects ingesting chromium chloride and chromium picolinate formulations. Conclusion: Our pooled analysis suggested that chromium supplementation might be a candidate as an adjunct to pharmacological management in patients with T2DM.

show abstract

Section: Resultsmentioning

confidence: 99%

Chromium supplementation for adjuvant treatment of type 2 diabetes mellitus: Results from a pooled analysis

Huang

Chen²,

Dong

et al. 2017

Molecular Nutrition Food Res

View full text Add to dashboard Cite

show abstract

“…Twenty RCTs (22 study arms) of patients with T2DM, including all in the existing meta-analyses and the one additional RCT 24 that had been completed after the last metaanalysis, are summarized in this report. A few studies controlled for or monitored background diets and physical activity levels, though most did not.…”

Section: Synthesizing the Results Of The Data Setmentioning

confidence: 99%

“…Abbreviations: Cr, chromium; IGT, impaired glucose tolerance; RCTs, randomized controlled trials. 22 Cefalu et al (2010) 23 Chen et al (2014) 24 Crawford et al (1999) 25 Evans (1989) 26 Ghosh et al (2002) 27 Gunton et al (2005) 28 Grant and McMullen. (1982) 29 Grant et al (1997) 30 Hermann et al (1998) 31 Hermann et al (1994) 32 Jain et al (2012) 40 Lee and Reasner (1994) 41 Li et al (1992) 42 Li (1994) 43 45 Martinez et al (1985) 46 Mossop (1983) 47 Offenbacher and Pi-Sunyer (1980) 48 Offenbacher et al (1985) 49 Pasman et al (1997) 50 Pei et al (2006) 51 Rabinovitz et al (1983) 52 Rabinovitz et al (2004) 53 Racek et al (2006) 54 Riales et al (1981) 55 Singer and Geohas (2006) 56 Sharma et al (2011) 57 Sherman et al (1968) 58 Thomas and Gropper (1996) 59 Urberg and Zemel (1987) …”

Section: Studies Measuring Hba1cmentioning

confidence: 99%

Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness

2016

View full text Add to dashboard Cite

Some adults with type 2 diabetes mellitus (T2DM) believe that chromium-containing supplements will help control their disease, but the evidence is mixed. This narrative review examines the efficacy of chromium supplements for improving glycemic control as measured by decreases in fasting plasma glucose (FPG) or hemoglobin A1c (HbA1c). Using systematic search criteria, 20 randomized controlled trials of chromium supplementation in T2DM patients were identified. Clinically meaningful treatment goals were defined as an FPG of 7.2 mmol/dL, a decline in HbA1c to 7%, or a decrease of 0.5% in HbA1c. In only a few randomized controlled trials did FPG (5 of 20), HbA1c (3 of 14), or both (1 of 14) reach the treatment goals with chromium supplementation. HbA1c declined by 0.5% in 5 of 14 studies. On the basis of the low strength of existing evidence, chromium supplements have limited effectiveness, and there is little rationale to recommend their use for glycemic control in patients with existing T2DM. Future meta-analyses should include only high-quality studies with similar forms of chromium and comparable inclusion/exclusion criteria to provide scientifically sound recommendations for clinicians.

show abstract

“…Changes in BMI were reported in eight trials and 19 trials reported changes in body weight . The reported mean BMI of all included trials was over 25 kg/m 2 , therefore all included participants were considered as subjects with overweight/obesity.…”

Section: Resultsmentioning

confidence: 99%

“…The reported mean BMI of all included trials was over 25 kg/m 2 , therefore all included participants were considered as subjects with overweight/obesity. Of the 21 RCTs, 12 reported body fat percentage, eight RCTs measured waist circumference and only three studies specified the waist to hip ratio . In terms of study quality, 13 trials were categorized as high‐quality with Jadad score of ≥3; and eight as low‐quality studies with Jadad score of <3 (Table ).…”

Section: Resultsmentioning

confidence: 99%

A meta‐analysis of the effect of chromium supplementation on anthropometric indices of subjects with overweight or obesity

et al. 2019

View full text Add to dashboard Cite

Summary The role of chromium as a weight loss agent remains questionable, and although previous meta‐analyses findings have reported small reductions in body weight in individuals with overweight/obesity following chromium supplementation, there have been significant limitations with these findings. The objective of this meta‐analysis was to evaluate the current evidence for the efficacy of oral chromium supplementation in individuals with overweight/obesity from randomized controlled trials. Studies were identified by a search of electronic databases from inception to November 2018 and combined and stratified analyses were used. Twenty‐one trials from 19 studies were identified which met all inclusion criteria which were suitable for statistical pooling, and data from 1316 participants were included. Pooled analysis showed significant reductions in anthropometric indices associated with body composition; for weight loss (weighted mean difference [WMD]: −0.75 kg, 95% confidence interval [CI], −1.04, −0.45, P < 0.001), body mass index (WMD: −0.40, 95% CI, −0.66, −0.13, P = 0.003 and body fat percentage (WMD: −0.68%, 95% CI, −1.32, −0.03, P = 0.04) in individuals with overweight/obesity. No changes were detected in controls. Subgroup analysis showed significant improvements in weight loss and body fat percentage, particularly for study durations ≤12 weeks and doses ≤400 μg/d. Chromium supplementation was associated with some improvements in body composition in subjects with obesity/overweight. The effect size was medium and the clinical relevance of chromium as a weight loss aid remains uncertain. Further investigation from larger and well‐designed randomized controlled studies, especially in patients with diabetes, is warranted.

show abstract

The effect of chromium on inflammatory markers, 1st and 2nd phase insulin secretion in type 2 diabetes

Cited by 31 publications

References 26 publications

Chromium supplementation for adjuvant treatment of type 2 diabetes mellitus: Results from a pooled analysis

Chromium supplementation for adjuvant treatment of type 2 diabetes mellitus: Results from a pooled analysis

Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness

A meta‐analysis of the effect of chromium supplementation on anthropometric indices of subjects with overweight or obesity

Contact Info

Product

Resources

About